Work

Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial

Year: 2024

Type: conference-abstract

DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1201

Authors: M. Bafadhel, S.A. Christenson, N.A. Hanania, S.P. Bhatt, K.F. Rabe, C.F. Vogelmeier, A. Papi, D. Singh, E. Laws, C. Nivens, A. Bansal, X. Lu, D. Bauer, J. Maloney, L.B. Robinson, R.M. Abdulai

Institutions: King's College London, University of California, San Francisco, Baylor College of Medicine, University of Alabama at Birmingham, German Center for Lung Research, LungenClinic Grosshansdorf, Philipps University of Marburg, University of Ferrara, University of Manchester, Manchester University NHS Foundation Trust, Sanofi (United States), Regeneron (United States)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396507175

Cites:

Cited by:

Related to: 10